Please use this identifier to cite or link to this item: http://nuir.lib.nu.ac.th/dspace/handle/123456789/5233
Full metadata record
DC FieldValueLanguage
dc.contributorMARISA KHUMYATen
dc.contributorมาริสา คุ้มญาติth
dc.contributor.advisorDumrongsak Pekthongen
dc.contributor.advisorดำรงศักดิ์ เป๊กทองth
dc.contributor.otherNaresuan University. Faculty of Pharmaceutical Sciencesen
dc.date.accessioned2023-03-23T02:17:10Z-
dc.date.available2023-03-23T02:17:10Z-
dc.date.issued2021en_US
dc.identifier.urihttp://nuir.lib.nu.ac.th/dspace/handle/123456789/5233-
dc.descriptionMaster of Science (M.S.)en
dc.descriptionวิทยาศาสตรมหาบัณฑิต (วท.ม.)th
dc.description.abstractBacopa monnieri (L) Wettst. (B. monnieri) has been beneficial for neuropharmacological disorders treatment. Herb-drugs interaction (HDIs) could occur due to inhibition or induction potential of drug metabolism enzymes. It could alter the pharmacokinetics and lead to toxicity or therapeutic failure. Currently, there are a few studies that reported B. monnieri extract could inhibit drug-metabolizing enzymes using rat liver microsome and human recombinant Cytochrome P450 (rCYPs). Those results align with an in vivo study that reported B. monnieri extract relatively inhibits CYP2C and 3A in rats after co-administration of B. monnieri extract and amitriptyline. However, no study regarding the inhibition potential on CYPs system using human liver microsome (HLMs) has been conducted. In addition, the induction potential of B. monnieri extract is still unclear. To achieve this purpose, the extract's inhibition, and the induction effect of the extract on CYP isoforms were evaluated using the in vitro gold standard models i.e., the pooled HLMs and primary human hepatocytes, respectively. As the results, B. monnieri extract demonstrates strongly inhibit CYP2C19 activity with IC50 values of 17.68 µg/mL, and moderate inhibit CYP1A2, 2B6, and 2C9 with IC50 values of 75.98, 59.69, and 47.72 µg/mL, respectively. Whereas this extract showed weak inhibition potential on CYP3A4 with IC50 values of 101.40 µg/mL. To solve the puzzle of inhibition mode of B. monnieri extract and bacopaside I which is assumed as a major bioactive compound derived from the pharmacological activity, the Lineweaver–Burk plots were conducted, and the secondary plots of Lineweaver-Burk plots were conducted to determine the inhibition constant (Ki) values. The results found that B. monnieri extract could inhibit CYP1A2 with competitive mode (Ki = 48.06 µg/mL) and inhibit CYP2B6, 2C9, and 2C19 (Ki = 5.16, 19.93, and 3.04 µg/mL, respectively) with mixed-type inhibition. In addition, the CYP2B6 was competitively inhibited by bacopaside I with Ki values of 7.02 µg/mL. Whereas this saponin glycoside could inhibit the CYP2C9 and CYP2C19 enzyme activity with mixed type inhibition (Ki = 25.92 and 13.25 µg/mL, respectively). Consequently, B. monnieri extracts also significantly enhanced the enzyme activity and mRNA expression of CYP1A2, and 2B6. In addition, the bacopaside I showed moderate inhibit CYP2B6 and CYP2C9 activity while others phytochemical compounds did not inhibit any CYPs isoform. Although in in vitro results demonstrated the inhibition and induction potential on the CYPs system, at oral administration of 300 mg/day B. monnieri extract, which is a recommended dose, may not produce HDIs. Since the predicted fraction absorbed of five major bioactive compounds did not exceed 20% and oral bioavailability was equal to 6.2% in humans after orally receiving 10 mg of isolated compounds. Besides, consuming the B. monnieri extract might not produce hepatotoxicity. Because of the cell viability are still over 75% when treated with B. monnieri extract at high concentration in primary human hepatocyte. However, oral intake of simultaneous medications and B. monnieri extract should be done with caution. It cannot conclude from the present study whether B. monnieri extract has been a cause of herb-drug or herb-herb interactions in humans.en
dc.description.abstract-th
dc.language.isoenen_US
dc.publisherNaresuan Universityen_US
dc.rightsNaresuan Universityen_US
dc.subjectInhibitionen
dc.subjectInductionen
dc.subjectBacopa monnierien
dc.subjectHerb-drugs interactionen
dc.subjectCytochrome P450en
dc.subjectEnzyme kineticsen
dc.subject.classificationPharmacologyen
dc.subject.classificationPharmacologyen
dc.subject.classificationPharmacologyen
dc.subject.classificationPharmacologyen
dc.subject.classificationPharmacologyen
dc.titleInhibitory and inductive effects of Bacopa monnieri standardized extract and its constituents on human liver cytochrome P450en
dc.titleผลของสารสกัดมาตรฐานพรมมิและส่วนประกอบในสารสกัดต่อการยับยั้งหรือเหนี่ยวนำการทำงานของเอนไซม์ไซโตโครมตับของมนุษย์th
dc.typeThesisen
dc.typeวิทยานิพนธ์th
Appears in Collections:คณะเภสัชศาสตร์

Files in This Item:
File Description SizeFormat 
62061450.pdf2.36 MBAdobe PDFView/Open


Items in NU Digital Repository are protected by copyright, with all rights reserved, unless otherwise indicated.